GW Pharma signs Sativex license deal with Novartis

A cannabis derived drug which has been approved in some countries to treat muscle spasticity.

GW Pharma signs Sativex license deal with Novartis

Postby MSUK » Mon Apr 11, 2011 3:42 am


U.K. drug maker GW Pharmaceuticals PLC said it has signed a license deal with Novartis AG to commercialize its cannabis-based multiple sclerosis treatment Sativex in a range of markets including Australia, parts of Asia and Africa.

Under the agreement, GW will get an upfront payment of $5 million and receive a further $28.75 million dependent on certain approvals and commercial milestones.

Novartis will have exclusive rights to sell Sativex in Australia; New Zealand; Asia, excluding Japan and China; the Middle East, excluding Israel; and Africa. Regulatory filings for the treatment will be submitted in some of these regions during 2011, GW said.... Read More - ... ageid/1814
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Sativex


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service